Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Onychomycosis: early-phase trial registry

A small indexed set (12 trials) with no open enrollment listed right now.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count

Onychomycosis: 12 US clinical trials tracked, none currently recruiting.

Onychomycosis is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Meiji Seika Pharma Co., running 2 of these trials.

Enrollment posture brief

Registry condition onychomycosis

OPEN 0 | RECR 0% | LATE 1 | EARLY 5 | RANK #1429 | SPON 2

Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%Onychomycosis (this)0%
Open-enrollment share among volume-matched conditions near Onychomycosis

Onychomycosis has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Onychomycosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Onychomycosis is recruiting below its size-band peers.

    0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Onychomycosis research.

    Meiji Seika Pharma Co. accounts for 2 of 12 trials (16.7%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Onychomycosis trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 12 trials that report a genuine target (sentinel values excluded). 9 of those (75%) plan for fewer than 100 participants.

  4. Onychomycosis research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 31

Indexed trials (enrollment closed)

12 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3 350 participants

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Moberg Pharma AB

NCT05279846

COMPLETED Phase 2 304 participants

Efficacy and Safety Study of ME1111 in Patients With Onychomycosis

Meiji Seika Pharma Co.

NCT02022215

COMPLETED NA 105 participants

Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus

Erchonia Corporation

NCT01534689

COMPLETED 50 participants

Spread of Dermatophytes Among Families

University Hospitals Cleveland Medical Center

NCT00233493

COMPLETED NA 50 participants

Diode Laser Treatment of Onychomycosis

ConBio, a Cynosure Company

NCT01452490

COMPLETED NA 30 participants

Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

Roxane Laboratories

NCT00602251

COMPLETED NA 30 participants

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

Roxane Laboratories

NCT00602342

COMPLETED NA 27 participants

Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser

Stanford University

NCT01666002

COMPLETED Phase 1 25 participants

Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis

Galderma R&D

NCT00941317

COMPLETED Phase 2 25 participants

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Nitric BioTherapeutics

NCT01484145

COMPLETED Phase 1 24 participants

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Meiji Seika Pharma Co.

NCT01841996

COMPLETED Phase 2 20 participants

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

Pfizer

NCT00679601

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Onychomycosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Terbinafine Drug
2 trials
Matching Vehicle Solution Drug
1 trials
ME1111 Solution, High strength Drug
1 trials
ME1111 Solution, Low strength Drug
1 trials
ME1111 solution Drug
1 trials
Terbinafine HCl Drug
1 trials
Pathformer (micro-drilling device) Device
1 trials
Diode Laser Treatment Device
1 trials

US sites by state

Facility locations filed on Onychomycosis trials. A trial with sites in several states counts in each.

Texas 3 trials
California 3 trials
Ohio 2 trials
New York 2 trials
Missouri 2 trials
Minnesota 2 trials
Michigan 2 trials
Indiana 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Onychomycosis page

12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Onychomycosis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Meiji Seika Pharma Co. sponsors the most Onychomycosis trials on record, review their full trial history before evaluating a specific study. See Meiji Seika Pharma Co.'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Onychomycosis condition card totals 12 registered trials; most-linked intervention Terbinafine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.